Progress in Clinical Research on Gonadotropin-Releasing Hormone Receptor Antagonists for the Treatment of Prostate Cancer

被引：9

作者：

Liu, Yi-Fu ^{[1
]}

Fu, Sheng-Qiang ^{[1
]}

Yan, Yu-Chang ^{[1
]}

Gong, Bin-Bin ^{[1
]}

Xie, Wen-Jie ^{[1
]}

Yang, Xiao-Rong ^{[1
]}

Sun, Ting ^{[1
]}

Ma, Ming ^{[1
]}

机构：

[1] Nanchang Univ, Affiliated Hosp 1, Dept Urol, Nanchang 330000, Jiangxi, Peoples R China

来源：

DRUG DESIGN DEVELOPMENT AND THERAPY | 2021年 / 15卷

关键词：

gonadotropin-releasing hormone; prostate cancer; degarelix; relugolix; ANDROGEN-DEPRIVATION THERAPY; ANTIANDROGEN FLARE PROTECTION; URINARY-TRACT SYMPTOMS; III EXTENSION TRIAL; OF-LIFE IMPROVEMENT; OPEN-LABEL; GNRH ANTAGONIST; PHASE-II; JAPANESE PATIENTS; 1-ARM CROSSOVER;

D O I：

10.2147/DDDT.S291369

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Gonadotropin-releasing hormone (GnRH) receptor agonists are still the most commonly used androgen deprivation treatment (ADT) drugs for prostate cancer in clinical practice. Currently, the GnRH receptor antagonists used for endocrine therapy for prostate cancer primarily include degarelix and relugolix (TAK-385). The former is administered by subcutaneous injection, while the latter is an oral drug. Compared to GnRH agonists, GnRH antagonists reduce serum testosterone levels more rapidly without an initial testosterone surge or subsequent microsurges. This review focuses on the mechanism of action of GnRH antagonists and agonists, the developmental history of GnRH antagonists, and emerging data from clinical studies of the two antagonists used as endocrine therapy for prostate cancer.

引用

页码：639 / 649

页数：11

共 50 条

[41] Gonadoliberin (Gonadotropin-Releasing Hormone), Its Agonists and Antagonists
Holicka, Martina
Vyslouzil, Jakub
Kubova, Katerina
Muselik, Jan
Vetchy, David
CHEMICKE LISTY, 2021, 115 (10): : 516 - 523
[42] Gonadotropin-releasing hormone antagonists in controlled ovarian stimulation
Diedrich, Klaus
Felberbaum, Ricardo
Al-Hasani, Safaa
GYNAKOLOGE, 2020, 53 (08): : 517 - 521
[43] A potential new use for gonadotropin-releasing hormone antagonists
Aust, TR
Sklavounos, J
Kingsland, CR
Gazvani, R
FERTILITY AND STERILITY, 2003, 80 (03) : 641 - 642
[44] Role of gonadotropin-releasing hormone antagonists in poor responders
Mahutte, Neal G.
Arici, Aydin
FERTILITY AND STERILITY, 2007, 87 (02) : 241 - 249
[45] DESIGN OF POTENT CYCLIC GONADOTROPIN-RELEASING HORMONE ANTAGONISTS
RIVIER, J
KUPRYSZEWSKI, G
VARGA, J
PORTER, J
RIVIER, C
PERRIN, M
HAGLER, A
STRUTHERS, S
CORRIGAN, A
VALE, W
JOURNAL OF MEDICINAL CHEMISTRY, 1988, 31 (03) : 677 - 682
[46] Human myometrium and leiomyomas express gonadotropin-releasing hormone 2 and gonadotropin-releasing hormone 2 receptor
Parker, Jason D.
Malik, Minnie
Catherino, William H.
FERTILITY AND STERILITY, 2007, 88 (01) : 39 - 46
[47] Pulsatile gonadotropin-releasing hormone treatment
Strowitzki T.
Gynäkologische Endokrinologie, 2016, 14 (4) : 245 - 248
[48] Identification and characterization of the gonadotropin-releasing hormone response elements in the mouse gonadotropin-releasing hormone receptor gene
Norwitz, ER
Cardona, GR
Jeong, KH
Chin, WW
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (02) : 867 - 880
[49] CLINICAL EFFECTS OF GONADOTROPIN-RELEASING HORMONE ANALOG IN METASTATIC CARCINOMA OF PROSTATE
SMITH, JA
GLODE, LM
WETTLAUFER, JN
STEIN, BS
GLASS, AG
MAX, DT
ANBAR, D
JAGST, CL
MURPHY, GP
UROLOGY, 1985, 25 (02) : 106 - 114
[50] Cardiovascular Outcomes Associated With Gonadotropin-Releasing Hormone Antagonists vs GonadotropinReleasing Hormone Agonists for Prostate Cancer Treatment: A MetaAnalysis of Randomized Controlled Trials
Jaiswal, Vikash
Jaiswal, Akash
Saleeb, Marina
Jha, Mayank
Hanif, Muhammad
Kalra, Kriti
Evbayekha, Endurance O.
Agrawal, Vibhor
Ang, Song Peng
Zacks, Jerome S.
CIRCULATION, 2023, 148

← 1 2 3 4 5 →